{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:25:35Z","timestamp":1769693135464,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myonectin, a newly discovered myokine, enhances fatty acid uptake in cultured adipocytes and hepatocytes and suppresses circulating levels of free fatty acids in mice. This study is performed to evaluate the association between serum and aqueous humor myonectin concentrations with diabetic retinopathy (DR). This study was performed in a population of 228 patients with type 2 diabetes (T2DM) and 72 control subjects. Diabetic patients were then divided into T2DM patients without DR, non-proliferative diabetic retinopathy (NPDR) patients, and proliferative diabetic retinopathy (PDR) patients. Serum and aqueous humor myonectin concentrations were significantly lower in the case group than in the control group. PDR patients showed significantly decreased serum and aqueous humor myonectin concentrations than in the other two T2DM patients. In addition, NPDR patients showed significantly lower serum and aqueous humor myonectin concentrations than T2DM patients without DR. Logistic regression analysis demonstrated that serum and aqueous humor myonectin was correlated with a decreased risk of T2DM and DR. Simple linear regression analysis showed that serum myonectin was negatively correlated with duration of disease, body mass index (BMI), and HbA1c. Duration of disease and BMI were still correlated with the serum myonectin after a multiple linear regression analysis. Aqueous humor myonectin was negatively correlated with duration of disease, systolic blood pressure (SBP), and diastolic blood pressure. Duration of disease and SBP was still correlated with the aqueous humor myonectin after a multiple linear regression analysis. Our investigation indicates an inverse association of serum and aqueous humor myonectin with DR.<\/jats:p>","DOI":"10.1038\/s41598-021-86677-2","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T10:03:41Z","timestamp":1617098621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of serum and aqueous humor myonectin concentrations with diabetic retinopathy"],"prefix":"10.1038","volume":"11","author":[{"given":"Huibo","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenchao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"86677_CR1","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.2337\/diacare.27.10.2540","volume":"27","author":"DS Fong","year":"2004","unstructured":"Fong, D. S. et al. Diabetic retinopathy. Diabetes Care 27, 2540\u20132553 (2004).","journal-title":"Diabetes Care"},{"key":"86677_CR2","doi-asserted-by":"publisher","first-page":"854593","DOI":"10.1155\/2015\/854593","volume":"2015","author":"M Al-Shabrawey","year":"2015","unstructured":"Al-Shabrawey, M., Zhang, W. & McDonald, D. Diabetic retinopathy: Mechanism, diagnosis, prevention, and treatment. Biomed Res. Int. 2015, 854593 (2015).","journal-title":"Biomed Res. Int."},{"key":"86677_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","volume":"30","author":"J Tang","year":"2011","unstructured":"Tang, J. & Kern, T. S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 30, 343\u2013358 (2011).","journal-title":"Prog. Retin. Eye Res."},{"key":"86677_CR4","doi-asserted-by":"publisher","first-page":"11968","DOI":"10.1074\/jbc.M111.336834","volume":"287","author":"MM Seldin","year":"2012","unstructured":"Seldin, M. M. et al. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J. Biol. Chem. 287, 11968\u201311980 (2012).","journal-title":"J. Biol. Chem."},{"key":"86677_CR5","doi-asserted-by":"publisher","first-page":"E88","DOI":"10.1210\/jc.2011-1743","volume":"97","author":"S Lim","year":"2012","unstructured":"Lim, S. et al. Effects of aerobic exercise training on C1q tumor necrosis factor \u03b1-related protein isoform 5 (myonectin): Association with insulin resistance and mitochondrial DNA density in women. J. Clin. Endocrinol. Metab. 97, E88\u2013E93 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"86677_CR6","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1161\/CIRCRESAHA.118.313777","volume":"123","author":"N Otaka","year":"2018","unstructured":"Otaka, N. et al. Myonectin is an exercise-induced myokine that protects the heart from ischemia\u2013reperfusion injury. Circ. Res. 123, 1326\u20131338 (2018).","journal-title":"Circ. Res."},{"key":"86677_CR7","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","volume":"110","author":"CP Wilkinson","year":"2003","unstructured":"Wilkinson, C. P. et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110, 1677\u20131682 (2003).","journal-title":"Ophthalmology"},{"key":"86677_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s10238-020-00654-z","volume":"20","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Decreased serum myonectin concentrations in diabetic nephropathy patients. Clin. Exp. Med. 20, 601\u2013607 (2020).","journal-title":"Clin. Exp. Med."},{"key":"86677_CR9","doi-asserted-by":"publisher","DOI":"10.1055\/a-0896-8548","author":"Z Li","year":"2019","unstructured":"Li, Z. et al. Circulating serum myonectin levels in obesity and type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes. https:\/\/doi.org\/10.1055\/a-0896-8548 (2019).","journal-title":"Exp. Clin. Endocrinol. Diabetes."},{"key":"86677_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1210\/jc.2017-01604","volume":"103","author":"K Li","year":"2018","unstructured":"Li, K. et al. Myonectin predicts the development of type 2 diabetes. J. Clin. Endocrinol. Metab. 103, 139\u2013147 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"86677_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/13813455.2019.1675713","author":"A Shokoohi Nahrkhalaji","year":"2019","unstructured":"Shokoohi Nahrkhalaji, A. et al. Higher serum level of CTRP15 in patients with coronary artery disease is associated with disease severity, body mass index and insulin resistance. Arch. Physiol. Biochem. https:\/\/doi.org\/10.1080\/13813455.2019.1675713 (2019).","journal-title":"Arch. Physiol. Biochem."},{"key":"86677_CR12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41598-020-57877-z","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Implications of C1q\/TNF-related protein superfamily in patients with coronary artery disease. Sci. Rep. 10, 878 (2020).","journal-title":"Sci. Rep."},{"key":"86677_CR13","doi-asserted-by":"publisher","first-page":"E1816","DOI":"10.3390\/ijms19061816","volume":"19","author":"W Wang","year":"2018","unstructured":"Wang, W. & Lo, A. C. Y. Diabetic retinopathy: Pathophysiology and treatments. Int. J. Mol. Sci. 19, E1816 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"86677_CR14","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/sj.eye.6702138","volume":"20","author":"N Demircan","year":"2006","unstructured":"Demircan, N. et al. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond.) 20, 1366\u20131369 (2006).","journal-title":"Eye (Lond.)"},{"key":"86677_CR15","doi-asserted-by":"publisher","first-page":"E4755","DOI":"10.3390\/ijms20194755","volume":"20","author":"H Youngblood","year":"2019","unstructured":"Youngblood, H. et al. Proteomic biomarkers of retinal inflammation in diabetic retinopathy. Int. J. Mol. Sci. 20, E4755 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"86677_CR16","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2014-06-584607","volume":"124","author":"L Kautz","year":"2014","unstructured":"Kautz, L. et al. Erythroferrone contributes to recovery from anemia of inflammation. Blood 124, 2569\u20132574 (2014).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86677-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86677-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86677-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:03:05Z","timestamp":1670047385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86677-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86677"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86677-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7215"}}